We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography (CLOSE-UP I)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01001663
First Posted: October 26, 2009
Last Update Posted: September 6, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Vingmed Danmark A/S
Information provided by (Responsible Party):
Niels Ramsing Holm, Aarhus University Hospital Skejby
  Purpose
Is the FemoSeal® closure device safer and more comfortable than manual compression for femoral artery access closure after coronary angiography?

Condition Intervention Phase
Coronary Angiography Via Femoral Artery Access Device: FemoSeal® Other: Manual compression Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography: the CLOSE-UP I Randomized Trial

Further study details as provided by Niels Ramsing Holm, Aarhus University Hospital Skejby:

Primary Outcome Measures:
  • Rate of ipsilateral palpable groin hematomas with largest diameter exceeding 5 cm. [ Time Frame: 20 minutes, 1 hour and at discharge, pooled ]

Secondary Outcome Measures:
  • Rate of ipsilateral palpable groin hematomas with largest diameter exceeding 5 cm. Patient self-measurements. [ Time Frame: 14 days ]
  • Composite of: major vascular complications necessitating surgical repair, A-V fistulation, pseudoaneurysm needing treatment, major bleeding needing transfusion and infection needing antibiotics . [ Time Frame: 14 days ]
  • Time to hemostasis, from sheath removal to hemostasis is achieved [ Time Frame: 14 days ]
  • Time from end of closure procedure to ambulation. 1h bedrest recommended. [ Time Frame: 14 days ]
  • Device deployment failure [ Time Frame: 20 minutes ]
  • Time to cessation of continuous minor oozing measured from the end of the closure procedure [ Time Frame: 14 days ]
  • Need for repeated manual compression after end of the closure procedure [ Time Frame: 14 days ]
  • Pain and discomfort measured on a numerical pain rating scale (0-10) [ Time Frame: 20 min ]
  • Vasovagal reaction (clinical signs AND Systolic BP drop of more than 30 mmHg AND/OR pulse drop more than 30 b/min. AND reversible immediately after treatment by atropin, fluids) [ Time Frame: 20 minutes ]
  • The patient seeking medical assistance for all-cause closure site related symptoms after discharge. [ Time Frame: 14 days ]
  • Pain and discomfort measured on a numerical pain rating scale (0-10) [ Time Frame: 1 hour ]
  • Pain and discomfort measured on a numerical pain rating scale (0-10) [ Time Frame: Discharge ]
  • Pain and discomfort measured on a numerical pain rating scale (0-10) [ Time Frame: 14 days ]

Enrollment: 1005
Study Start Date: September 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FemoSeal®
Closure device for femoral artery access closure
Device: FemoSeal®
Closure device for femoral artery access closure
Active Comparator: Manual compression
Conventional manual compression
Other: Manual compression
Conventional manual compression

Detailed Description:
Access site complication after coronary angiography is still a challenge in everyday practice. The FemoSeal® closure device has proven very safe as shown in the swedish SCAAR registry. This study is aimed to investigate, in a randomized design, if the FemoSeal® has an advantage in safety and efficacy over manual compression.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient must be at least 18 years old
  • Patients undergoing femoral access coronary angiography
  • Patient must be competent for providing informed, written consent
  • Only 6F sheath

Exclusion Criteria:

  • Percutaneous coronary intervention
  • Intra coronary measurements (FFR, IVUS, OCT, NIR)
  • Groin hematoma before closure
  • Pseudoaneurysm or AV fistula
  • Significant stenosis of ilial or femoral artery
  • Prior peripheral artery surgery
  • INR > 3,0
  • Platelet count < 120 million per millilitre blood
  • Coagulopathy (bleeding disorder)
  • Thrombolysis in the last 24h
  • Planned heparin infusion after the procedure
  • Pregnancy
  • Uncontrolled hypertension > 200 mmHg / 110 mmHg
  • Femoral access device closure in the last 30 days
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01001663


Locations
Denmark
Aarhus University Hospital Skejby
Aarhus N, Denmark, 8200
Sponsors and Collaborators
Aarhus University Hospital Skejby
Vingmed Danmark A/S
Investigators
Principal Investigator: Niels R. Holm, MD Aarhus University Hospital Skejby